Clinical grade ACE2 as a universal agent to block SARS‐CoV‐2 variants is a research paper published in EMBO Molecular Medicine (2022). On theSindex it has a DataRank of 0.598. It has been cited 53 times.
Scored on demand from live citation data
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.598
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Austrian Science Fund
Grant: Z 271‐B19
Canada 150 Chair
Grant: F18‐01336
Center for Strategic Scientific Initiatives, National Cancer Institute
Grant: 75N91019D00024
Center for Strategic Scientific Initiatives, National Cancer Institute
Grant: 75N91019F00130
Gouvernement du Canada ¦ Canadian Institutes of Health Research
Grant: F20‐02343
Gouvernement du Canada ¦ Canadian Institutes of Health Research
Grant: F20‐02015
Innovative Medicines Initiative
Grant: 101005026
Swiss National Science Foundation
Grant: P400PM_194473
FWCI
4.82
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords